Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. SomnoMed Limited
  6. News
  7. Summary
    SOM   AU000000SOM1

SOMNOMED LIMITED

(SOM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Somnomed Limited : SomnoMed appoints new Head for North Amercian region

09/26/2012 | 09:52pm EDT

SOMNOMED APPOINTS NEW HEAD FOR NORTH AMERICAN REGION

27th September 2012: SomnoMed announced today the appointment of Kien T. Nguyen as President for
SomnoMed Inc., the US subsidiary of SomnoMed Limited.
Kien has a lifelong career in the healthcare industry, working for leading companies such as Stryker Corporation, Kinetic Concepts, Inc. (KCI) and various medical device divisions of Johnson & Johnson. Most recently, he was Vice President and General Manager of OtisMed, a business unit of Stryker Orthopaedics, a division of the $8 billion Stryker Corporation. At KCI, he fulfilled various functional Vice President positions, including Global Portfolio Management, Global Research & Ideation, and Global Marketing of the Active Healing Solutions division, with revenues responsibilities of $1.4 billion. Most of his earlier career was spent with Ethicon, Inc., a Johnson & Johnson company, where he held roles in product development, product marketing, clinical sales and finally as Worldwide Marketing Director for the biosurgical business unit within Johnson & Johnson Wound Management.
"We are very pleased to have been able to gain Kien Nguyen as our new head of our North American business. Kien is an outstanding individual with an impeccable career, focused on strategy development and marketing & sales in medical devices and biological products. His academic background is exemplary with an MBA from Columbia Business School, a doctorate (Neuroscience) from University of Colorado and a Master of Science (Microbiology) from Minnesota State University. His past business successes were based on solid knowledge of the key factors influencing medical specialists and decision makers and his great personality allowing him to attract talent around him and lead a team to success," said Dr. Peter Neustadt, Executive Chairman of SomnoMed Limited.
"This appointment is significant for SomnoMed's business in the US and Canada, being our most important markets. Kien will work closely with me and report to SomnoMed's board on a monthly basis. Over the last three months all directors were directly involved in the recruitment of the President for SomnoMed Inc. and the quality of executives interviewed was outstanding. After an extensive search process all directors were of the opinion that Kien was the candidate of choice and the executive most likely to succeed in building a significant business for our company in North America in the future," said Dr. Neustadt.
Kien was born in Vietnam and came to the US as a young child. As a refugee of the war, he had to take early responsibility for his education, putting himself through college working as a surgical technician at the Mayo Clinic, and earning a Bachelor of Science degree in Genetics and Cell Biology from the University of Minnesota. Post baccalaureate, he joined Lark Sequencing Technologies, Inc., as a molecular biologist. He is married and has two sons.
Kien Nguyen will be based at the North American head office in Frisco, TX. His appointment will take effect on 5 November 2012.
About SomnoMed
SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 100,000 patients in 22 countries. For additional information, visit SomnoMed at http://www.somnomed.com.

distributed by

© Publicnow 2012
All news about SOMNOMED LIMITED
09/03ADDVANTAGE TECHNOLOGIES : Names Michael Rutledge Finance Chief
MT
08/23Somnomed Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
03/21SOMNOMED LIMITED(ASX : SOM) dropped from S&P/ASX All Ordinaries Index
CI
02/22SomnoMed Limited Reports Earnings Results for the Half Year Ended December 31, 2020
CI
2020Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020
CI
2020SomnoMed Limited Reports Unaudited Revenue Results for the First Quarter of 2021
CI
2020Somnomed Limited Reports Earnings Results for the Full Year Ended June 30, 2020
CI
2020SomnoMed Limited Appoints New Directors, Effective August 24, 2020
CI
2020SomnoMed Announces Board Changes
CI
2020SOMNOMED LIMITED(ASX : SOM) added to S&P/ASX All Ordinaries Index
CI
More news
Financials
Sales 2022 74,1 M 55,3 M 55,3 M
Net income 2022 -3,26 M -2,43 M -2,43 M
Net cash 2022 15,0 M 11,2 M 11,2 M
P/E ratio 2022 -64,6x
Yield 2022 -
Capitalization 201 M 150 M 150 M
EV / Sales 2022 2,51x
EV / Sales 2023 2,19x
Nbr of Employees -
Free-Float 66,8%
Chart SOMNOMED LIMITED
Duration : Period :
SomnoMed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOMNOMED LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 2,43 AUD
Average target price 2,51 AUD
Spread / Average Target 3,09%
EPS Revisions
Managers and Directors
Neil Verdal-Austin Chief Executive Officer, MD & Director
Hervé Fiévet Chief Financial Officer
Guy Russo Non-Executive Chairman
Hamish Corlett Non-Executive Director
Hilton Brett Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SOMNOMED LIMITED15.71%150
ABBOTT LABORATORIES15.74%224 651
MEDTRONIC PLC5.08%165 656
BECTON, DICKINSON AND COMPANY-1.25%70 962
HOYA CORPORATION21.65%56 316
DEXCOM, INC.53.24%54 815